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Summary
Background—Immune tolerance induction (ITI) in patients with congenital hemophilia A is 
successful in up to 70%. Although there is growing understanding of predictors of response to ITI, 
the probability and predictors of inhibitor recurrence following successful ITI are not well 
understood.
Objectives—To determine the association of clinical characteristics, particularly adherence to 
FVIII prophylaxis following ITI, with inhibitor recurrence in patients with hemophilia A who 
were considered tolerant following ITI.
Methods—In this multicenter retrospective cohort study, 64 subjects with FVIII level <2% who 
were considered successfully tolerant following ITI were analyzed to estimate the cumulative 
probability of inhibitor recurrence using the Kaplan-Meier method. The association of clinical 
characteristics with inhibitor recurrence was assessed using logistic regression.
Results—A recurrent inhibitor titer ≥ 0.6 BU/ml occurred at least once in 19 (29.7%) and more 
than once in 12 (18.8%). The probability of any recurrent inhibitor at 1 and 5 years was 12.8% and 
32.5% respectively. Having a recurrent inhibitor was associated with having received immune 
modulation during ITI (OR 3.8, 95% CI: 1.2-22.4) and FVIII recovery of <85% at the end of ITI 
(OR 2.6, 95% CI: 1.3-5.9), but was not associated with adherence to post-ITI prophylactic FVIII 
infusion (OR=0.5, 95% CI: 0.06-4.3).
Conclusions—The use of immune modulation therapy during ITI and lower FVIII recovery at 
the end of ITI appear to be associated with an increased risk of inhibitor recurrence following 
successful ITI. Adherence to post-ITI prophylactic FVIII infusions is not a major determinant of 
recurrence.
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Introduction
Formation of anti-factor VIII (FVIII) inhibitory antibodies (inhibitor) is the major 
complication of treatment of hemophilia A. Currently, immune tolerance induction (ITI) via 
regular infusion of FVIII is the most effective method to eradicate the inhibitor and is 
successful in about 70% of patients [1, 2]. ITI outcomes are influenced by both host and 
treatment regimen-related factors. Characteristics that are considered to be predictors of 
successful ITI include starting ITI at a young age, short duration between the onset of 
inhibitor and start of ITI, lower historical peak inhibitor titer (<200 BU/ml), lower inhibitor 
titer just prior to the start of ITI (<10 BU/ml), lower peak inhibitor titer on ITI (<100 
BU/ml) and low risk F8 gene mutations such as small insertions, small deletions, and 
missense mutations [1-3]. Once tolerance is achieved, little is known about the probability of 
inhibitor recurrence or the clinical or treatment-related characteristics that are influential in 
maintaining tolerance. In clinical practice, continued regular exposure to FVIII (prophylactic 
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treatment) is thought to be imperative for maintaining tolerance, but this has not been 
formally evaluated.
The overall purpose of this study is to estimate predictors of inhibitor recurrence after 
successful ITI and to determine the impact of poor adherence to prophylactic FVIII 
treatment following ITI and other clinical characteristics on inhibitor recurrence.
Methods and patients
Participants
After Institutional Review Board approval at 12 US Comprehensive Hemophilia Treatment 
centers, potential subjects were identified by review of patient databases. Patients with 
hemophilia A and a history of an inhibitor who successfully completed a course of ITI using 
a locally prescribed regimen between 1/1/1998 and 8/15/2010 were enrolled in the study. 
For this analysis, only subjects with negative inhibitor titer and normalized FVIII recovery 
(>66%) and/or FVIII half-life (>6 hours) to document successful tolerance were included.
Study Variables
Data for clinical demographic variables was obtained through retrospective review of the 
medical record and recorded on a standardized case report form. The primary outcome was 
FVIII inhibitor recurrence defined as any inhibitor titer ≥0.6 BU/ml following successful 
ITI. A secondary definition of inhibitor recurrence was 2 or more elevated inhibitor titers 
(≥0.6 BU/ml). The primary independent variable of interest was adherence during the 6 
months prior to inhibitor recurrence or the last negative inhibitor titer. Adherence was 
determined by comparing the actual treatment regimen (as determined by infusion logs/
calendars and/or pharmacy information) with the prescribed treatment regimen [(# actual 
infusions/#prescribed infusions) × 100]. Subjects were considered adherent to post-ITI 
prophylaxis if they had received > 80% of their prescribed infusions [4]. Other variables 
collected included: subject demographics (year of birth, race, ethnicity, family history of 
hemophilia and inhibitor), hemophilia history (FVIII level, F8 mutation: high risk mutations 
were those including intron 22, and intron 1 inversion, large deletions [>50 base pairs] and 
nonsense mutations) [5, 6], inhibitor characteristics (initial inhibitor titer, peak inhibitor titer 
prior to the start of ITI [historical peak], inhibitor titer at the start of ITI), characteristics of 
ITI regimen (product used, whether the reported successful course of ITI was the first course 
of ITI, dose category, frequency of infusion, duration, use of concomitant immune 
modulating agents, and FVIII recovery and half-life at the end of ITI), seropositivity for 
HIV or HCV at the time tolerance was achieved.
Statistical Analysis
Descriptive statistics were calculated for all variables. To determine associations between 
clinical variables and inhibitor recurrence, all variables were initially considered using 
univariate analysis. For each variable of interest, Chi-square test, Fisher's exact test or 
Wilcoxon-signed rank tests were used, as appropriate, to examine the relationship between 
inhibitor recurrence and the potential risk factor.
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The cumulative probability of inhibitor recurrence was determined using Kaplan Meier 
method. The time of follow-up was from confirmation of successful tolerance induction as 
defined by a negative inhibitor titer and FVIII recovery >66% and/or FVIII half-life > 6 
hours and continued until the last recorded negative inhibitor titer (<0.6 BU/ml) or inhibitor 
recurrence (inhibitor titer ≥0.6 BU/ml). Smoothed survival curves were constructed based on 
parametric probability estimates derived from the HAZARD procedure in SAS (http://
www.clevelandclinic.org/heartcenter/hazard). This procedure uses maximum likelihood 
estimates to resolve risk distribution of time to event in up to 3 phases of risk (early, 
constant and late).
The association of adherence and other variables with the outcome of interest, recurrent 
FVIII inhibitor, was analyzed using a logistic regression model. Cox proportional hazards 
model was also performed, but since relevant variables violated the Cox proportional 
hazards assumptions, the logistic model is presented here. In the first model, adherence was 
the predictor of interest and included in the model. In this model, propensity scoring was 
used to adjust for variables that were associated with adherence on bivariable analysis and 
therefore potentially confounding the association between adherence and inhibitor 
recurrence. Frequency of FVIII infusions during ITI (once or twice daily vs. three to four 
times a week), duration of ITI and historical peak inhibitor titer were variables included in 
the propensity score. The propensity score had a receiver operating curve (ROC) of 0.8. A 
second model was built to evaluate other predictors of inhibitor recurrence by including 
variables significant on bivariable analysis at the 0.10 level or known to be associated with 
successful ITI (historical peak titer, pre-ITI titer, peak titer during ITI [< or ≥ 100 BU/ml], 
time to ITI start [< or ≥ 2 years]). For this model additional dichotomized variables were, 
FVIII recovery, < or ≥ 85%, after assessing the sensitivity and specificity of multiple 
different cut points (70-90%) and dose of FVIII used for ITI, < or ≥ than 100 IU/kg. 
Variables were kept in the model if they were associated with inhibitor recurrence (p<0.10) 
or confounded the association between another exposure variable and the outcome, inhibitor 
recurrence. Variables that were not included based on their bivariable association or known 
association with ITI success were individually evaluated in the model. For multivariable 
logistic modeling, exact odds ratios are reported with mid-p correct exact p-values. The 
McFadden R2 was used to measure fit of the logistic regression models. Values between 0.2 
and 0.4 indicated good model fit (Louviere et al. 2000, Stated Choice Methods: Analysis and 
Applications, Cambridge University Press). SAS version 9.3 (Cary, NC) was used to 
perform all analyses.
Results
One hundred eighteen patients that completed ITI between 1/1/1998 and 8/15/2010 were 
reviewed to determine if ITI was considered clinically successful or not. Ninety-one patients 
(77%) were considered by their treating center to have successfully completed ITI based on 
the local institutional criteria during the 12 year and 8 months time span. Of the latter 91 
who were considered to have successfully completed ITI, 7 were excluded due to lack of 
available documentation of a negative inhibitor titer at the end of ITI, resulting in a total of 
84 patients were enrolled on study (Fig.1). Neither FVIII recovery nor FVIII half-life was 
available in 17 subjects. The population for this analyses was further limited to include only 
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subjects with a FVIII level <2% (n=64), since the biology of disease may be different for 
those with milder hemophilia and the population was not adequately represented (n=3) to 
allow for adjustment or comparison. Sixty four patients with FVIII activity <2% who had 
completed ITI were included in the analysis.
Tolerance was characterized by a negative inhibitor titer and FVIII recovery >66% in 36 
(56.3%) patients, a negative inhibitor titer and FVIII half-life without FVIII recovery in 1 
(1.6%), and a negative inhibitor titer, FVIII recovery >66%, and FVIII half-life >6 hours in 
27 (42.2%). The median age at inhibitor diagnosis was 1.6 years (Q1, Q3: 1, 3.3) and the 
median age ITI was initiated was 3.3 years (Q1, Q3: 1.5, 8.5) (Table 1). Seventy-two percent 
of patients (n=46) were White and 18.7% (n=12) were Black race; 25% (n=16) were 
Hispanic ethnicity. Nearly all patients, 62 (96.9%) had severe FVIII deficiency. Sixty 
percent (n=39) had a positive family history of hemophilia, 33.3% (n=13) of whom had a 
sibling, uncle or cousin with a history of an inhibitor. Of the 31 with known F8 mutations; 
25 had high risk mutations (18 intron 22 inversion, 1 intron 1 inversion, 2 large deletions, 
and 4 nonsense mutations) and 6 had low risk mutations (2 small deletion/insertion, 2 splice 
site and 2 missense mutations). Few patients were HIV (4.7%) or hepatitis C antibody 
positive (9.4%). A recombinant product was used during ITI in 57 (89%) patients. The daily 
dose of FVIII used during ITI varied widely and included 2 (3.1%) patients who received 
<50 IU/kg/day, 13 (20.3%) who received 51-99 IU/kg/day, 42 (65.6%) who received 
≥100-199 IU/kg/day and 7 (10.9%) patients who received ≥200 IU/kg/day. The majority of 
patients, 59 (92.2%), were treated with FVIII infusions alone whereas 5 (7.8%) received at 
least one immune modulatory therapy in conjunction with ITI (Table 2). None of these 5 
treated with immune modulating therapy during the reported successful course of ITI had 
previously failed a prior attempted course of ITI. In the overall cohort, only 3 subjects had 
previously received ITI unsuccessfully. Demographic and clinical characteristics of the 20 
subjects enrolled but not included in the analysis cohort were not different from the 64 
included (data not shown).
Adherence to post-ITI prophylaxis
Due to missing records adherence to post-ITI FVIII prophylaxis could not be assessed in 6 
subjects (9.3%). Among the 58 of patients in whom adherence was assessed, 41 (70%) were 
adherent to post-ITI FVIII prophylaxis, infusing 80% or more of prescribed treatment during 
the 6 months prior to inhibitor recurrence or last follow up (Fig. 1). Of the 17 subjects who 
were not adherent to post-ITI FVIII prophylaxis, only 1 person had discontinued FVIII 
infusions altogether.
Inhibitor recurrence
The median duration of follow-up from confirmation of tolerance with FVIII recovery or 
FVIII half-life to inhibitor recurrence or last negative inhibitor titer was 3.4 years (Q1, Q3: 
1.2, 7.0). The probability of any inhibitor recurrence at one, three and five years was 12.8 % 
(95% CI, 9.4-17.2), 26.6% (95% CI, 21.4-32.6) and 32.5% (95% CI, 27.7-39), respectively, 
as shown by the Kaplan-Meier inhibitor free survival curve (Fig. 2a). The probability of 
recurrence in those subjects with more than one inhibitor titer (N=12) at one, three and five 
years was 7.3% (95% CI, 4.9-10.7), 17.1% (95% CI, 12.7-22.5) and 22.5% (95% CI, 
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17.2-28.8), respectively (Fig. 2b). Of those with only 1 inhibitor titer as evidence of 
recurrence (n=7), 1 subject had a single high-titer inhibitor (>5 BU/ml) without a change in 
treatment, 4 subjects had a low-titer and no change in therapy, and 2 subjects with low-titer 
inhibitors and change in treatment, 1 restarted ITI and 1 received an increased dose of FVIII 
to manage bleeding without restarting ITI. Of those with more than one elevated inhibitor 
titer at the time of recurrence (n=12) 8 (66.7%) were high-titer, 10 (83.3%) restarted ITI, and 
10 (83.3%) received a bypassing agent for treatment of bleeding. Of the 11 (1 after only 1 
recurrent inhibitor titer and 10 after more than 1 recurrent inhibitor titer) that restarted ITI, 2 
achieved tolerance for a second time, 3 did not, and 6 were still receiving ITI at the time of 
the study data collection.
Predictors of inhibitor recurrence
A recurrent FVIII inhibitor was detected in 12 (29%) of those adherent to post-ITI 
prophylaxis, 5 (29%) in those not adherent, and 2 (33%) for whom adherence could not be 
assessed (Fig. 1).
When comparing subjects with (n=19) and without inhibitor recurrence (n=45), there was no 
statistically significant differences in the median age at the time of inhibitor onset (1.2 vs. 
1.8 years) and no difference in the age when ITI was initiated (3.2 vs. 3.3 years) (Table 1). 
There was no difference in inhibitor recurrence by race (p=0.74), by presence of high-risk 
mutations (p=0.95), nor by historical peak inhibitor titer, pre-ITI titer or peak titer during ITI 
(p >0.2 for each).
There were no differences in the ITI-regimen-related characteristics among subjects with 
and without a recurrent inhibitor, including whether it was the first course of ITI, the FVIII 
product used for ITI (recombinant vs. non-recombinant), frequency of FVIII infusions 
during ITI (once or twice daily vs. three-four times a week), dose of FVIII used for ITI (> or 
< 100 IU/kg/day) or duration of ITI in years. Among the 5 patients who received immune 
modulatory therapy as part of their ITI regimen, 4 (80%) experienced an inhibitor recurrence 
(p <0.01), while the single patient (20%) who received plasmapheresis did not (Table 2). To 
assess for confounding by indication, characteristics that might lead to the use of 
immunosuppression were compared between those that did and did not receive 
immunosuppression (Table 3). The duration of ITI was slightly longer in those who received 
immunosuppression [2.2 years (Q1, Q3: 1.2, 2.4)] compared with those that did not [1.1 
years (Q1, Q3: 0.5, 2)] and the proportion of subjects who had a peak titer >100 BU/ml 
during ITI was greater (40%) in those who received immunosuppression than those that did 
not (6.8%).
Among those with and without a recurrent inhibitor titer, tolerance was documented by a 
FVIII recovery level only in 63% (n=12) and 53% (n=24) and both FVIII recovery level and 
FVIII half-life in 37% (n=7) and 44% (n=20), respectively. Tolerance was documented by 
FVIII half-life without FVIII recovery level in 2.2% (n=1) subject without a recurrent 
inhibitor. A sensitivity analysis showed that FVIII recovery of less than 85% had a 
sensitivity of 79% and specificity of 59% (p <0.01) for predicting inhibitor recurrence. The 
median FVIII recovery was 79% (Q1, Q3: 74, 85) in those with and 89% (Q1, Q3: 70, 106) 
in those without inhibitor recurrence (p=0.03). Half-life was reported in a similar proportion 
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of subjects with FVIII recovery level > or < 85% (50% and 42% respectively). Among the 
28 subjects with a reported FVIII half-life, there was no difference in half-life between those 
with and without inhibitor recurrence (p=0.18).
During the 6 months prior to inhibitor recurrence or the last negative inhibitor titer, 12 
subjects underwent surgery; 6 developed a recurrent inhibitor and 6 did not. The surgical 
procedures in those with a recurrent inhibitor included port placement, port removal, dental 
procedure, and creation of an arteriovenous fistula, and 3 of these were complicated by an 
infection. In those without a recurrent inhibitor, surgical procedures included port placement 
and removal, right total knee replacement and Broviac repair, and none were complicated by 
an infection.
Multivariable Analysis
After adjustment for age, race, and the propensity score, which included frequency of FVIII 
infusions during ITI, duration of ITI, and historical peak inhibitor titer, adherence to 
prophylactic FVIII infusions following ITI was not a predictor of having any recurrent FVIII 
inhibitor (adjusted OR=0.5 [95% CI: 0.06-4.3], p=0.53).
In the second model, after adjusting for a peak inhibitor titer of > 100 BU/ml after the 
initiation of ITI and the duration of ITI, having FVIII recovery of <85% at the end of ITI 
and use of concomitant immune modulatory therapy were shown to be independently 
associated with inhibitor recurrence (OR 2.6 [95% CI:1.3-5.9] and 3.8 [95%, CI 1.2-22.4] 
respectively) regardless of the end point used, (one or more than one recurrent inhibitor) 
(Table 4). A time lapse of over 2 years from inhibitor onset to the start of ITI trended 
towards a statistically significant association, OR of 2.0 (95% CI: 0.9-4.6), (p=0.09). No 
other variables in the model appeared to be associated or demonstrated confounding. A 
sensitivity analysis was performed by excluding the three subjects who previously had an 
unsuccessful course of ITI and similar results of multivariable models were obtained.
Discussion
The analysis of this retrospective cohort demonstrates a significant risk of recurrent inhibitor 
following successful ITI that is associated with low FVIII recovery level and the use of 
immune modulatory therapy during ITI, but not with adherence to post-ITI FVIII 
prophylaxis.
The overall proportion of subjects who experienced a recurrent FVIII inhibitor reported in 
this study, 29.7%, is higher than the rates reported in the NAITR, IITR and PROFIT studies 
of 10%, 4.6% and 2.3%, respectively [1, 3, 7]. There are several potential reasons for these 
differences: first the stringency of the definition of tolerance varied among the studies. In the 
PROFIT study, subjects were not considered tolerant until one year following normalization 
of recovery and FVIII half-life; this may have excluded early relapses that occurred due to 
insufficient induction of tolerance. In the current study there was a higher, though not 
statistically significant, rate of inhibitor recurrence in those subjects without clear 
documentation of their half-life at the end of ITI. A similar observation was made in the 
NAITR study [1]. Secondly, the studies differed in their definition of inhibitor recurrence. In 
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this study, the definition of recurrent inhibitor was any inhibitor titer ≥0.6 BU/ml after the 
end of ITI. When a more rigorous definition of 2 elevated inhibitor titers was used, the rate 
of recurrence is lower but still higher than previously published results (7.3% at 1 year and 
22.5% at 5 years). Importantly, no inhibitor recurrence was detected after 5 or more years of 
completion of successful ITI, with 35.9% of the cohort being observed for at last 5 years. In 
the PROFIT and IITR study, a single recurrent inhibitor was detected at 7 and 15 years, 
respectively [3, 7], suggesting that the risk is present but low.
In contrast to the general perception in clinical practice, lack of adherence to post-ITI FVIII 
prophylaxis was not predictive of inhibitor recurrence on both bivariable and multivariable 
analyses. Despite this, there are other compelling reasons for patients to be adherent to FVIII 
infusions such as prevention of joint bleeding and avoidance of subsequent disability. 
Unfortunately, in this small cohort, it was not possible to assess whether the influence of 
adherence to post-ITI FVIII prophylaxis on inhibitor recurrence changes over time. It is 
conceivable that post-ITI prophylaxis is more important early in the post-ITI course, 
becoming less important with time following ITI, but this remains unknown.
Factor VIII recovery was found to be associated with inhibitor recurrence: a FVIII recovery 
level less than 85% was associated with 3-fold greater odds for inhibitor recurrence than 
when a FVIII recovery level of greater than 85%. Currently, a level greater than 66% is used 
in clinical practice as indicative of emerging tolerance. It is important to note that in pivotal 
clinical trials of FVIII, the median recovery of children aged 1-6 years was 1.84 IU/dl per 
IU/kg which is 92% of predicted, and the lowest quartile of children had a recovery <1.64 
IU/dl per IU/kg which is 82% of predicted [8]. In the IITI study, the 6 subjects with partial 
relapses during the first year after ITI [3] did not differ from the rest of the cohort in their 
FVIII recovery (92.5%) and FVIII half-life (7.0 hours) at the end of ITI. The lack of impact 
of FVIII recovery at the end of ITI in the IITI study may reflect that they were only partial 
relapses (negative inhibitor titer but reduced recovery) and the median recovery in the IITI 
study was 92.5%, indicating that the majority of subjects had a >85% FVIII recovery at the 
end of ITI. Ideally, this finding that a FVIII recovery <85% is predictive of inhibitor 
recurrence should be confirmed in other cohorts or on prospective investigation. Our 
findings could also reflect a lack of consistent washout prior to measurement of recovery. 
Given that this was a retrospective study, the duration of FVIII washout prior to measuring 
the FVIII recovery was not prescribed nor was this information collected. It is possible that 
in the absence of a sufficient FVIII washout, a recovery of 66-85% may represent an 
inadequate FVIII recovery that would likely be <66% following an adequate 48-72 hour 
FVIII washout. With either of these two explanations, these data, along with the IITI study 
median FVIII recovery of 92.5%, suggest that measurement of FVIII recovery at the end of 
ITI is an important marker of emerging tolerance and should be measured carefully.
There is no consensus about the use of immune modulation in conjunction with ITI as a first 
line therapy. In our study, those receiving immune modulatory therapy in conjunction with 
ITI showed no difference in historical peak inhibitor titer, inhibitor titer prior to the start of 
ITI, or peak inhibitor titer after ITI compared with those that did not receive immune 
modulatory therapy. The median duration of ITI appeared to be longer (2.2 years vs. 1.1 
years) (Table 3), suggesting that immune modulation may have been started as the result of 
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a clinical perception of lack of adequate response to ITI alone. Three of the 4 patients who 
relapsed received rituximab (Table 2). Although these worse outcomes could be the result of 
more refractory disease, it is also possible that rituximab reduced the inhibitor titer, but did 
not promote tolerance, leading to withdrawal of ITI following rituximab due to a false 
perception of tolerance. Notably, the time to relapse among patients that received immune 
modulation was markedly shorter compared to those who did not (0.42 years vs. 3.8 years, 
respectively; p=0.001). In the cohort study published by Collins et al, of 6 subjects receiving 
rituximab as part of ITI; 3 (50%) recurred, 2 remained tolerant after 3.5 and 2 years, and 1 
had limited follow-up of only 16 weeks, suggesting that the tolerance induction with 
rituximab may be less effective and/or less durable, but this will require prospective study to 
resolve [9]. There are no reports on the impact of other immunosuppressive agents such as 
cyclophosphamide and mycophenolate on the durability of tolerance in hemophilia A. One 
may speculate that mycophenolate, in addition to suppressing effector T cells, may also 
suppress T regulatory cells thereby limiting the maintenance of a tolerant milieu.
There are several strengths and limitations of this study. One strength of the study is the 
multi-institutional design, thereby representing real world practice from a broad distribution 
of patients from 12 U.S. hemophilia treatment centers. The limitation of this study is its 
small sample size resulting in limited power and potential risk of overestimating the effect 
size. Additionally, as is the case with any observational study, there is a concern for 
unmeasured confounding. Lastly, despite an effort to include all potential subjects through 
review of clinical databases at each center, there is a possibility that some patients were 
omitted.
In summary, this study demonstrates that the probability of inhibitor recurrence is significant 
in the first five years after ITI, and is associated with a FVIII recovery of < 85% at the end 
of ITI, and the use of concomitant immune modulation therapy during ITI, but not 
adherence to post-ITI prophylaxis. These findings suggest that following ITI, patients should 
be carefully monitored for inhibitor recurrence, particularly those who have received 
immune modulation such as rituximab. Ideally the influence of recovery level and the use of 
immune modulation would be investigated in a larger prospective study to better elucidate 
the most effective practice.
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Figure 1. Subject flow chart
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Kaplan Meier survival curves to estimate probability of any inhibitor recurrence, n=19 (A) 
and more than one inhibitor recurrence, n=12 (B). Dashed lines represent 95% confidence 
intervals.
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Table 1
Characteristics of study cohort








 Age at inhibitor onset, y 1.6 (1,3.3) 1.2 (0.7,2.9) 1.8 (1.1,3.5) 0.20
 Age at start ITI, y 3.3 (1.5,8.5) 3.2 (1.1,6.8) 3.3 (1.5,11.4) 0.55
 Race 0.74
  White 46 (71.9) 15 (78.9) 31 (68.9)
  Black 12 (18.8) 3 (15.8) 9 (20.0)
  Other 6 (9.3) 1 (5.3) 5 (11.1)
 Hispanic ethnicity 16 (25.0) 6 (31.6) 10 (22.2) 0.53
Hemophilia and health history
 Severe Hemophilia 62 (96.9) 18 (94.7) 44 (97.8) 1.0
 Family History of inhibitor 13 (20.3) 4 (21.1) 9 (20.0) 0.92
 F8 genotype (n=31) 0.95
  High-risk 25 (80.6) 8 (80.0) 17 (80.9)
  Low-risk 6 (19.4) 2 (20.0) 4 (19.0)
 HIV positive 3 (4.7) 0 3 (6.7)
 Hepatitis C antibody positive 6 (9.4) 2 (10.5) 4 (8.9) 1.0
Inhibitor characteristics
 Historical peak titer (BU/ml) 9.9 (3.8,34) 11.2 (3,38) 8.5 (4.5,30) 0.77
 Historical peak titer > 5 BU/ml 43 (67.2) 12 (63.1) 31 (68.9) 0.77
 Historical peak titer > 200 BU/ml 3 (4.7) 2 (10.5) 1 (2.2) 0.21
 Pre-ITI titer (BU/ml) 2.1 (1,5.5) 2.0 (1,4.5) 2.5 (1,5.5) 0.71
 Pre-ITI titer > 10 BU/ml 5 (7.8) 2 (10.5) 3 (6.7) 0.63
 Peak titer during ITI (BU/ml) 2.8 (0.5,33) 10 (0.6,40) 2.7 (0.5,24) 0.36
 Peak titer during ITI > 100 BU/ml 6 (9.4) 3 (15.8) 3 (6.7) 0.35
Characteristics of ITI
 Time from inhibitor onset to start ITI, y 0.75 (0.2,2.1) 1.1 (0.4,2.4) 0.6 (0.2,3.7) 0.67
 ITI started 2 years after inhibitor onset 14 (21.9) 5 (26.3) 9 (20.0) 0.74
 First course of ITI 61 (95.3) 18 (94.7) 43 (95.6) 1.0
 ITI with recombinant FVIII product 57 (89.1) 17 (89.5) 40 (88.9) 0.95
 ITI regimen, FVIII infusions ≥ daily 16 (84.2) 34 (75.6) 0.53
 Dose of FVIII use for ITI < 100 IU/kg/day 15 (23.4) 3 (15.8) 12 (26.7) 0.52
 Any immunosuppression used during ITI 5 (7.8) 4 (21.1) 1 (2.2) 0.007
 Duration of ITI, y 1.2 (0.6,2.0) 0.75 (0.4,2.2) 1.2 (0.6,2) 0.42
 Tolerance criteria met 0.71
  Negative titer/recovery > 66% 36 (56.3) 12 (63.2) 24 (53.3)
  Negative titer/half-life > 6h 1 (1.6) 0 1 (2.2)
  Negative titer/recovery/half-life 27 (42.2) 7 (36.8) 20 (44.4)
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 FVIII Recovery % (n=63) 85 (71,98) 79 (74,85) 89 (70,106) 0.03†
 FVIII half-life, hours (n=28) 8 (6,9.1) 7 (6,8) 8 (6.4,9.2) 0.18
After ITI
 Not adherent to post ITI FVIII prophylaxis 17 (26.6) 5 (26.3) 12 (26.7) 0.78
 Events during 6 months before recurrent 
inhibitor or last negative inhibitor titer 0.53
   Surgery 12 (18.8) 6 (31.6) 6 (13.3) 0.09
   Vaccination 3 (4.7) 0 3 (6.7)
   Serious bleed 1 (1.6) 0 1 (2.2)
   Infection 3 (4.7) 3 (15.8) 0
   Hospitalization 1 (1.6) 0 1 (2.2)
†
Kolmogorov-Smirnov two sample test. Y indicates years; BU indicates Bethesda unit; ITI indicates Immune tolerance induction; FVIII indicates 
factor VIII; h indicates hours;
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Table 3
Characteristics based on receipt of immunosuppression
Clinical Characteristics Immunosuppression Therapy
Yes N=5 No N=59 p-value
Race, White, n (%) 5 (100) 41(69.5) 0.34
Age at start of ITI, years, median (Q1,Q3) 1.1 (0.8,1.8) 3.4 (1.5, 10.3) 0.12
Time from inhibitor onset to start ITI, years, median (Q1,Q3) 1.1 (0.1, 15.6) 0.7 (0.2, 2.7) 0.80
 ≥ 2 years, n (%) 1 (20.0) 13 (22.0) 1.0
Historical peak titer, BU/ml, median (Q1,Q3) 25.9 (3,27) 9.8 (4,34) 0.79
 ≥ 200 BU/ml, n (%) 0 3 (5.1) -
Titer at start ITI, BU/ml, median (Q1,Q3) 2.0 (1.9,4) 2.1 (1,5.5) 0.59
Duration of ITI, years, median (Q1,Q3) 2.2 (1.2, 2.4) 1.1 (0,5.2) 0.39
Peak titer during ITI ≥ 100 BU/ml, n (%) 2 (40) 4 (6.8) 0.07
FVIII recovery level, %, median (Q1,Q3) 79 (75,85) 85 (71,98) 0.63
Tolerance Criteria Met 0.23
 Titer and FVIII recovery only 1 (20) 34 (57.6)
 Titer, FVIII recovery, and half-life 4 (80) 24 (40.7)
Time to relapse, years, median (Q1,Q3) 0.42 (0.39,0.56) 3.8 (1.8,7.0) 0.001













Antun et al. Page 17
Table 4
Multivariable logistic regression model
Variables OR 95% CI p-value
≤ 85% FVIII Recovery 2.6 (1.3 – 5.9) 0.007
Immunosuppression therapy used in ITI 3.8 (1.2 – 22.4) 0.02
≥ 2 years from inhibitor onset to start ITI 2.0 (0.9 – 4.6) 0.09
Adjusted for peak inhibitor titer during ITI > 100 BU/ml and duration of ITI
ROC: 0.78 (0.67 – 0.90),
R2McF = 1 – ln (LM) / ln (L0) = 0.24
LR Test for Model Fit p = 0.001
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